Should you exit small and mid-cap funds now?
Should you exit small and mid-cap funds now?

Should you exit small and mid-cap funds now?

Prakash Patil Article rating: 4.0

With the markets going into correction and consolidation mode, the year 2018 has been disappointing for the mid-cap and small-cap fund investors. These funds have corrected more than the large-cap funds and investors in these funds are clueless about their next course of action.

IPO Analysis: RITES Limited
IPO Analysis: RITES Limited

IPO Analysis: RITES Limited

Apurva Joshi Article rating: 4.4

Rites Limited, a Government company, is coming with an IPO which will open for subscription from June 20 to June 22, 2018. The issue consists of Offer for Sale (OFS) of 2,52,00,000 equity shares worth Rs 466.20 crores. The issue price band is between Rs 180-185 per equity share.

Pharma sector is the next darling of market
Pharma sector is the next darling of market

Pharma sector is the next darling of market

Nikhil Desai Article rating: 4.3

In the recent past, the mutual fund houses aligned their products to invest in the pharma sector. The sector which has seen a huge decline in the last couple of years is now a darling for the mutual fund houses. Recently, Mirae Assets and ICICI Pru announced new thematic schemes keenly focused on maximizing profits from the pharma sector stocks.

Dhunseri Petrochem to exits Egyptian JV
Dhunseri Petrochem to exits Egyptian JV

Dhunseri Petrochem to exits Egyptian JV

Gayathri Udyawar Article rating: 3.5

The company signed an agreement with Indorama Group to exit their joint venture company, Egyptian Indian Polyester Company (EIPET).


Dr. Reddys Lab receives approval for de-addiction film
Dr. Reddys Lab receives approval for de-addiction film

Dr. Reddys Lab receives approval for de-addiction film

Sanket Dewarkar Article rating: 4.7

Dr. Reddy's Laboratories has received final approval from the US drug regulator for launching Buprenorphine and Naloxone Sublingual Film in the US market. The product is being launched through an approved Risk Evaluation and Mitigation Strategy (REMS) Program.

Alembic continues rally as Panelav unit receives EIR
Alembic continues rally as Panelav unit receives EIR

Alembic continues rally as Panelav unit receives EIR

Nikita Singh Article rating: 3.0

The share price of pharma major Alembic Pharmaceuticals continued to surge in Friday’s trading session. The share price grew by 7 per cent on Friday as the company bagged EIR for its formulation facility at Panelav, Gujarat from the US Food and Drugs Association. 

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Shital Jibhe Article rating: 5.0

The markets on June 15, 2018 opened gap down. BSE Sensex is trading at 35,555.79, down by 44.03 points and the Nifty is trading at 10,800.80, down by 7.25 points. 

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Shital Jibhe Article rating: 4.0

Overall volumes in futures & options currently stand at 1.41 crore contracts with a turnover of Rs. 14,18,956.96 crore.

RSS
First29232924292529262928293029312932Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR